Ivermectin 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

Ivermectin placebo 12 mg / day for 3 days, in combination with paracetamol therapy (500 mg QID) for 14 days

COVID-19

ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Ivermectin

Placebo of ivermectin 12 mg / day for 3 days, in combination with standard paracetamol therapy (500 mg QID) for 14 days

Placebo

Stromectol. FDA Approved Package Insert 2009

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Multicenter, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of Ivermectin in Mild Virus-positive Subjects (SARS-CoV)-2 With or Without Symptoms

The subject is considered to have progressed to severe illness when one or more of the following criteria are present:
Breathing difficulty (≥30 breaths per minute);
Resting oxygen saturation ≤93%;
Severe complications such as: respiratory failure, need for mechanical ventilation, septic shock, non-respiratory organic failure.

Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.

School children will be administered with behavioral change communication sessions as an intervention

Behavioral Assessment of Children

Communicable Diseases in Children

Behavior Change Communication sessions will be used to promote knowledge and practices among young children and to prevent communicable diseases.
This will include, capacity building of teachers and students, health awareness sessions at the school and improving school physical environment

Behavior Change Communication to promote hygiene behavior

Aga khan University

Intervention to Promote Hygiene Behavior Among School Children

School-based Interventions to Promote Personal and Environmental Hygiene Among Children in Pakistan: Protocol for a Mixed Methods Study

Changes in knowledge and practice of school children regarding hygiene will be assessed. There are no sub-scales used in the study. All knowledge and practice related responses will be measured as scores (pre-post intervention). Scores will be summed together. Less than 50 will be considered as poor, minimum and maximum score for rest of the categories are 50-75 will be considered as Good and 75-100 as Excellent. Higher values in each of the three categories will represent better outcomes for knowledge and practice.

This will include assessment of the change in the prevalence of communicable diseases (diarrhea, typhoid, pneumonia, oral health infections, scabies, hepatitis and mosquito borne infections) through structured questionnaire. Proportions of the children with these conditions will be used to report the change. No scales or sub-scales will be used. Proportions specific for each diseases will be averaged out pre-post intervention study.

At this stage, I intend to disseminate the study results with researchers.

Nousheen Pradhan

Senior Instructor

Aga Khan University

Behavior change communication sessions will be administered to school children belonging to 1-5 grades in schools

This blend contains Ginko at 120 mg/day and Cistanche at 300 mg/day

This blend contains Ginko at 180 mg/day and Cistanche at 450 mg/day

Mental Fatigue

Fatigue

Chronic Fatigue Syndrome

Experimental: Nutrilite® Low dose

Experimental: Nutrilite® High dose

Placebo Comparator: Placebo

Effect of Ginko and Cistanche Against Fatigue Symptoms

A 60-Day Clinical Study to Evaluate Nutrilite Ginko Biloba Cistanche Tablets in Relieving the Symptoms of Chronic Fatigue Syndromes Compared to Negative Control

scabies/biegunka

Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms

Intervention to Promote Hygiene Behavior Among School Children

Effect of Ginko and Cistanche Against Fatigue Symptoms

Najbardziej kompletna baza danych ziół leczniczych poparta naukowo